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Abstract Treatment resistant hypertension (TRH), defined as
a blood pressure above goal despite treatment with optimally
tolerated doses of 3 antihypertensive agents of different clas-
ses, ideally including a diuretic, remains a significant problem
and its management an area of uncertainty for physicians. One
hypothesis is that resistant hypertension is due to abnormal
sodium retention, mediated by aldosterone breakthrough oc-
curring despite blockade of the renin-angiotensin-aldosterone
system with angiotensin converting enzyme inhibitors (ACEi)
or angiotensin receptor blockers (ARB). Thus, there has been
renewed interest in the use of mineralocorticoid receptor
blockers (MRB) to treat this condition. This article critically
evaluates new evidence supporting the use of MRB in TRH
published in the last 3 years. We conclude that there is now
sufficient evidence to recommend MRB, in particular
spironolactone, as the first choice medication to treat this con-
dition, and for its inclusion in future guidelines.
Keywords Resistant hypertension .Mineralocorticoid
receptor blockers . Spironolactone . Eplerenone
Introduction
Hypertension is the single largest risk factor for death world-
wide, accounting for an estimated annual 9.4 million deaths
and 7 % of total disability life adjusted years globally in 2010
[1]. Treatment resistant hypertension (TRH), defined as hav-
ing a blood pressure of ≥140/90 mmHg despite at least 3
antihypertensive drugs, ideally including a diuretic [2], re-
mains a significant problem, estimated to affect up to 8 % of
patients identified from registry data using 24-h ambulatory
blood pressure monitoring (ABPM) [3]. TRH may be
regarded as ‘apparent’ or ‘true’ depending on whether other
causes of hypertension have been fully excluded and whether
un-remediated lifestyle factors such as obesity and high die-
tary salt intake have been adequately addressed (Fig. 1).
The optimal drug choice in TRH is not agreed.
Observational studies have shown a significant positive asso-
ciation between greater plasma aldosterone levels and blood
pressure in both non-hypertensive [5] and hypertensive [6]
populations, as well as a greater prevalence of primary
hyperaldosteronism in those with TRH [7]. Although multiple
contributory causes are likely responsible for TRH, one po-
tential mechanism is the phenomena of aldosterone ‘break-
through’ whereby aldosterone levels rise to normal levels de-
spite treatment with angiotensin converting enzyme inhibitors
(ACEi) or angiotensin receptor blockers (ARB). This occurs
in 10 % of patients treated with ACEi/ARBs over 6 months,
and >50 % over 1 year, leading to excess sodium retention,
hypertension and other adverse cardiovascular effects [8].
This hypothesis has revived interest in the use of mineralocor-
ticoid receptor blockers (MRB), in particular spironolactone
and eplerenone, to treat this problem.
The purpose of this article is to critically review the use of
MRB in TRH, focusing on evidence published in the last
3 years. It does not consider other approaches to the treatment
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of TRH, such as renal denervation, or the critical issue of
ensuring adherence to treatment.
Use of MRBs in the Treatment of TRH
Spironolactone, developed in the 1950s, and the epoxy deriv-
ative eplerenone, developed in the 1980s, are the two currently
available MRBs. Eplerenone has up to 500-fold less affinity
for androgen and progesterone receptors compared to
spironolactone, reducing the side effects of painful
gynaecomastia in men and menstrual disturbances in women.
However, eplerenone is a less potent MRB than
spironolactone (IC50 MR: eplerenone 81nM; spironolactone
2nM) [9], leading to a greater antihypertensive potency of
spironolactone than eplerenone [10].
Evidence for the use of spironolactone for the treatment of
TRH prior to the last 3 years in observational studies [11, 12]
and clinical trials [13–15] is supportive, as is the case for
eplerenone [16, 17], although insufficient to alter treatment
guidelines. As a result, significant new trials have been pub-
lished in the last 3 years.
New Evidence from the Past 3 Years
Sources and Selection Criteria
A literature search was performed for relevant studies between
January 2013 and December 2015 using PubMed, the
Cochrane Library and EMBASE with the search terms ‘hy-
pertension’, ‘resistant hypertension’, combined sequentially
with ‘spironolactone’, ‘eplerenone’, ‘mineralocorticoid recep-
tor blocker’, and ‘mineralocorticoid receptor antagonist’.
Studies were selected according to the criteria of (1) English
language (2) human subjects (3) adults (4) meta-analyses, ran-
domized active or placebo-controlled trials, prospective stud-
ies, and observational studies with control groups. Using this
approach, we identified 7 clinical trials and 2 meta-analyses
summarized in Table 1, which will now be briefly discussed.
All used spironolactone as the MRB.
Clinical Trials in Abstract Form
Djoumessi et al. [18] compared spironolactone with alterna-
tive medication in 17 patients with type 2 diabetes and TRH in
a randomized single-blind trial, published only in abstract
form thus limiting its interpretation and appraisal. After
1 month, patients on spironolactone showed a significantly
greater fall in home systolic BP than those on alternatives,
systolic BP falling from baseline in the spironolactone group
by 33 mmHg compared with 14 mmHg in the alternative
treatment group (p<0.001). No significant changes in plasma
creatinine or potassium were observed in either group.
Although encouraging in its support for the BP-lowering ef-
fect of spironolactone in TRH, this was a small open-label trial
without 24-hour ABPM. The alternative treatments were not
specified, so no practical conclusion can be drawn.
Published Clinical Trials
Oxlund et al. [19•] compared the addition of spironolactone
25 mg od or placebo to the treatment of 119 patients with type
2 diabetes and TRH in a double-blind, randomized, placebo-
controlled trial. All patients were treated with ACEI and/or
ARBs together with diuretics, with 66 % patients in the
spironolactone group and 69 % in the placebo group being
obese (BMI >30 kg/m2).
Fig. 1 Algorithm for diagnosis of
treatment resistant hypertension
(TRH). TRH should be
considered a provisional
diagnosis dependent on adequate
remediation of lifestyle and drug
related factors and exclusion of
secondary causes. Adapted from
[4]
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At 16 weeks, average daytime placebo-corrected BP was
reduced by 8.9 (4.7 to 13.2)/3.7 (1.5 to 5.8) mmHg (p<0.001)
in the spironolactone-treated group. One patient in the
spironolactone group discontinued treatment and three pa-
tients required dose reductions due to hyperkalaemia, with
one additional patient stopping treatment due to symptomatic
hypotension. The strengths of this study are that it used 24-h
ABPM in a population with type 2 diabetes, the relatively long
duration of 16 weeks and good trial design. The main limita-
tion is comparison with placebo, which precludes comparing
how effective spironolactone is against other commonly used
antihypertensive medications. In addition, medication adher-
ence was assessed by counting returned tablets rather than
biochemical blood or urine analysis. Although the white male
predominance may limit generalizability to females and other
ethnic groups, obesity and type 2 diabetes are very common
comorbidities in our clinic population; thus, overall, this study
is supportive for the efficacy and safety of spironolactone in
TRH.
The ASPIRANT-EXT trial [25] compared the effect of
adding spironolactone 25 mg od or placebo in 150 patients
with TRH in a randomized double-blind placebo-controlled
trial. At 8 weeks, both systolic and diastolic daytime 24-h
blood pressures in the spironolactone group were significantly
lower than that in the placebo (−11.5 [±13.4] vs −1.7 [±13.9]
mmHg, p<0.001 and −5.6 [±8.5] vs −2.3 mmHg, p<0.001).
Serum sodium was significantly lower and potassium signif-
icantly higher in the spironolactone group than in the placebo
at 8 weeks although no one discontinued treatment due to
hyperkalaemia or renal impairment. There was no significant
difference in adverse events or serious adverse events between
the treatment groups. Strengths of this study include the rela-
tively large sample size and use of 24-h ABPM at baseline and
as the endpoint. The major weaknesses include lack of checks
on patient adherence prior to enrolment, comparison to a pla-
cebo, which does not provide information about comparative
efficacy to other antihypertensive agents, and a relatively short
treatment duration of 8 weeks. The lack of black and diabetic
patients may limit the generalizability of these results. Overall,
this study supports the efficacy and safety for the use of
spironolactone in patients with TRH albeit not in comparison
to other antihypertensive agents.
Xiaoying Ni et al. [21] conducted a prospective random-
ized, double-blind trial comparing the effects of 12-week
treatment with spironolactone 25 mg od versus placebo in
82 patients with TRH on dialysis. When corrected for the
change in BP in the placebo group, the average morning BP
was reduced by 17.0 (16 to 18)/8 (6.1 to 10) mmHg and the
average 24-h BP was reduced by 12.5 (11.2 to 13.8)/7.0 (5.4
to 8.6) mmHg. The strengths of this study include its design
and inclusion of diuretics as part of the definition of TRH and
longer treatment duration of 12 weeks. The major weakness
is, as before, the use of a placebo. Thus while supportive of the
beneficial effect of spironolactone in TRH, this study does not
tell us what the best treatment is and is not generalizable to the
wider population of non-dialysis patients.
Verdalles et al. [23] conducted a prospective observational
open-label study comparing the effect of spironolactone
25 mg od or furosemide 40 mg od in 30 patients with TRH
attending a nephrology outpatient clinic. Patients with TRH
were assigned treatment with either spironolactone or furose-
mide as per the usual clinical practice of the treating physician.
Spironolactone treatment led to a significantly greater reduc-
tion in both systolic and diastolic BP at 24 weeks compared to
baseline than furosemide (−24 [±9.2] vs −13.8 [±2.8] mmHg
for systolic, −11 [±8.1] vs −5.2 [±2.2] mmHg for diastolic,
both p<0.01). Furthermore, there was no significant change
in eGFR in either group at 24 weeks compared to baseline,
with two patients developing mild hyperkalaemia in the
spironolactone group though they did not discontinue treat-
ment. The strengths of this study include the use of ABPM at
baseline, 12 and 24 weeks to exclude the effect of white coat
hypertension, the relatively long duration of 24 weeks, spec-
ification of a diuretic as part of the drug regimen as those
defined as having TRH, and inclusion of patients with renal
impairment, the mean eGFR being 55.8 [±16.5] mL/min/
1.73 m2. Although this study is supportive of the use of
spironolactone in patients with renal impairment and TRH, it
has serious limitations that restrict the wider conclusions that
can be drawn. Most importantly, this was a small open-label
non-randomized observational study which inherently cannot
exclude selection bias between the two treatment groups. The
method by which patient adherence was checked prior to en-
rolment was not specified, and the use of furosemide as the
sole comparator to spironolactone did not allow the effects of
alternative treatments, such as β blockers, to be compared.
Thus, overall, this study adds little to support the use of
spironolactone in TRH.
While the previously discussed trials have compared
spironolactone to either placebo or alternative medical treat-
ments, Rosa et al. [22] compared spironolactone to renal de-
nervation therapy in 106 patients with TRH in a randomized
open-label study. At 24 weeks there was a significant fall in
mean systolic BP measured by ABPM in both treatment arms
(−8.6 mmHg with renal denervation, p < 0.001 versus
−8.1 mmHg with intensified pharmacotherapy, p= 0.001),
but no significant difference between the two groups
(p=0.36). At 24 weeks, compared to baseline, the proportion
of patients treated with an MRB in the intensified pharmaco-
therapy group increased from 25 to 61 % (p<0.001), while
there was no significant change in the number of patients
prescribed amiloride, β blockers, α blockers and centrally
acting agents. The between-group 24-h systolic BP difference,
however, remained nonsignificant (p=0.46) when the number
of drugs and MRB use were adjusted for. Disregarding the
renal denervation arm of this trial, controversial following
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failure of the SIMPLICITY-3 trial to show a benefit of renal
denervation [26], the use of ABPM, the long treatment dura-
tion and use of drug assays to confirm adherence are the
strengths of this study. Unfortunately, although spironolactone
does appear to have been the most commonly added drug in
the intensified pharmacotherapy arm, which did show a sig-
nificant reduction in BP from baseline, its use was not the
main focus of this study which somewhat limits further inter-
pretation of these results in the context of specifically address-
ing the efficacy of spironolactone in TRH.
The most important and recent new evidence for the effec-
tiveness of MRB in TRH is the PATHWAY-2 study by
Williams et al. [24••] published in the Lancet. In this random-
ized double-blind crossover trial, patients with hypertension
resistant to 3 drugs including a diuretic were sequentially
treated with spironolactone (n=285), anα1 blocker doxazosin
(n = 282), β blocker bisoprolol (n = 285) and a placebo
(n=274), each for 12 weeks, in random order, with 230 pa-
tients completing all treatment arms. Spironolactone treatment
led to significantly greater mean reductions in systolic blood
pressure compared to placebo (−10 [−11.7 to −8.74] mmHg,
p<0.001), doxazosin (−5.64 [−69.1 to −4.36], p<0.001) and
bisoprolol (−5.98 [−7.45 to −4.51] mmHg, p <0.0001) on
home systolic BP readings taken at the final visit of each
treatment cycle. The magnitude of BP lowering with
spironolactone was inversely proportional to plasma renin
concentration, an association not observed with either
bisoprolol or doxazosin, supporting the role of sodium reten-
tion, volume expansion and low plasma renin in TRH. Aswell
as clearly demonstrating the superiority of spironolactone as
the most effective add-on medication in TRH compared to
bisoprolol and doxazosin, spironolactone was shown to be
safe and well tolerated with no greater discontinuation rate
due to renal impairment and hyperkalaemia with
spironolactone than the other treatments.
This trial has a number of important design strengths
that radically improve upon all previous published stud-
ies. Most importantly, it is the first trial to compare the
effect of spironolactone to other commonly used antihy-
pertensive drugs as well as placebo. In addition, home BP
monitoring was used as part of screening for eligibility to
assess adherence by measurement of BP 6 h after directly
observed therapy, as well for the primary endpoint of av-
erage of home systolic BP recorded throughout the treat-
ment cycle. This likely reduced the potential confounding
influence of non-adherence which has previously been
found to be an important factor in TRH [27•] as well as
allowing the exclusion of white coat hypertension. Other
strengths included a standardized definition of TRH to
include a diuretic in all enrolled patients, a longer 12-
week duration of treatment, measurement of serum ACE
to assess if patients were adherent with ACE inhibitor
medication, and a crossover design, which enabled
comparison of the effectiveness of medications in individ-
ual patients.
Limitations of the study include exclusion of patients with
moderate renal impairment (eGFR<45 mL/min/1.73 m2),
lack of a washout period between switching treatment group,
exclusion of type 1 diabetics and a low proportion of black
patients. Overall, however, these results provide robust new
evidence supporting the use of spironolactone in TRH, for the
first time giving clinicians clear guidance on the best treatment
among commonly used alternatives.
Meta-Analyses
Two meta-analyses combining the results of several studies of
spironolactone in resistant hypertension conducted over the
previous several years were published in 2015. Neither includ-
ed the PATHWAY-2 study.
The meta-analysis by Dahal et al. 2015 [28] included 15
studies in total published between 2002 and 2013 comprising
3 randomized controlled trials (135 patients in total treated
with MRB vs 136 control), 1 non-randomized comparative
study and 11 observational studies (898 patients in total treat-
ed with MRB). Only 1 study exclusively used eplerenone, 12
used spironolactone, and 2 studies used both eplerenone and
spironolactone. Follow-up varied from 5 to 40 weeks. Meta-
analysis of the combined results of the 4 fcomparative studies
demonstrated that spironolactone reduced pooled mean office
systolic BP by 24.3 [8.65 to 39.9] mmHg (p = 0.002,
I2 =95 %), while meta-analysis of the observational studies
showed a pooled mean reduction in office systolic BP of
22.7 mmHg (18.2 to 27.3, p<0.00001, I2=96 %). MRB were
not associated with an increased risk of hyperkalaemia com-
pared to placebo in the comparative studies (risk ratio=2.93
[0.5 to 18.1], p=0.25, I2=0%) although an increased risk was
noted in the observational studies.
Hongyin Guo et al. [29] systematically reviewed 8 studies
published between 2002 and 2013, comprising 5 observation-
al (1806 patients in total, all treated with spironolactone) and 3
(270 patients in total, 135 treated with spironolactone) ran-
domized placebo-controlled trials encompassing 2051 pa-
tients in total involving patients with TRH. Follow-up dura-
tion was between 4 and 24 weeks. Analysis of the combined
results of the 3 controlled studies showed spironolactone to
reduce pooled mean systolic BP by 20.6 (36.5 to 4.7) mmHg
compared to placebo (p<0.00001), while analysis of the 4
observational studies which had 24 weeks of follow-up
showed a fall in pooled mean systolic BP of 20.7 (25.6 to
15.8) mmHg, p<0.00001, after spironolactone treatment.
High levels of heterogeneity were noted between both con-
trolled and observational studies (I2 = 98 % and I2 = 81 %,
respectively), meaning these results just as with Dahal et al.
2015 [28] should be interpreted with considerable caution.
Although the consistent direction of benefit of spironolactone
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in TRH is reassuring, they both highlight the poor quality of
the evidence base comprised of small placebo-controlled trials
and observational studies prior to the publication of
PATHWAY-2. In addition, they did not address the important
clinical question of identifying the most effective drug for
TRH.
Discussion
Until the publication of PATHWAY-2, the overall quality of
evidence in support of the use of MRB in TRH has been poor
despite a general concordance over its positive therapeutic
effect in both observational and interventional studies.
Methodological issues of inadequate sample sizes, short trial
durations and use of a placebo as a comparator have all beset
previous work. As a consequence, support for the efficacy and
safety of MRB in TRH has been weak, reflected in the low
grade of its recommendation in current major treatment
guidelines.
PATHWAY-2 has been vital in finally addressing the limi-
tations of previous studies in particular by using active com-
parators of widely used antihypertensive medications in addi-
tion to a placebo. Furthermore, it provides the first biological
jus t i f i ca t ion for use of MRB in a non-pr imary
hyperaldosteronism population by the analysis of the BP re-
sponse to different treatments with respect to plasma renin
levels, indicating that sodium retention may play an important
role in TRH. PATHWAY-2 is an excellent example of the
importance of specialist society-led and charitably funded
drug trials not driven by a commercial imperative.
However, further questions remain to be resolved. In par-
ticular, we lack sufficient data on the use of MRB in patients
with mild to moderate renal impairment, and in diabetic and
black patients. In addition, we do not yet know whether treat-
ment with higher doses of thiazide and thiazide-like diuretics,
or potassium sparing diuretics such as amiloride, may be
equally effective.
As always, translating the results of clinical trials into day-
to-day care often proves less than straightforward, and, despite
routinely using spironolactone in our specialist hypertension
service for several years, significant challenges remain.
Managing patients with multiple drug intolerances, with renal
impairment and significant lifestyle issues all remain common
problems we see each week and which present important bar-
riers to good hypertension control. Indeed, a recent study
using routine screening for medication adherence confirmed
high levels of medication non-adherence in patients attending
a specialist hypertension clinic [27•]. This only serves to high-
light that while drug treatments such as spironolactone can be
effective, they are only part of a holistic approach
encompassing education and motivation to achieve lifestyle
change and good drug adherence.
Conclusion
We believe sufficient evidence has now accumulated to rec-
ommend spironolactone as the first choice drug for TRH and
hope clinical guidelines and algorithms will soon be updated
to reflect this important new evidence.
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